Please ensure Javascript is enabled for purposes of website accessibility

Curaleaf Posts 205% Q4 Revenue Growth, Announces $286 Million Deal for European Peer

By Eric Volkman - Updated Mar 10, 2021 at 8:13AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Acquisitions helped propel revenue higher, and are sure to continue doing so.

Curaleaf Holdings (CURLF 0.74%) had an eventful Tuesday, reporting both its latest quarterly results and a fresh acquisition after market hours.

As for the former, Curaleaf booked nearly $230.3 million in total revenue in its fourth quarter. That's an all-time high for the company and is up 26% from the previous quarter and a frothy 205% on a year-over-year basis. Net loss, however, deepened from both periods -- it was almost $35.3 million, against the third-quarter shortfall of $9.3 million and fourth quarter 2019's $26.6 million.

Happy woman holding marijuana seedling.

Image source: Getty Images.

However, on marijuana companies' favored profitability metric -- adjusted EBITDA -- Curaleaf was in the black, to the tune of nearly $53.8 million. The respective figures for the previous quarter and the year-ago period were $42.3 million and $13.8 million, respectively.

The company's top line was affected, as in quarters past, by acquisition activity. "Curaleaf's record Q4 results reflected the benefit of our acquisition of Grassroots, which expanded our presence into 6 new states," the company quoted its CEO Joe Bayern as saying. The six include the marijuana hotbed of Illinois and populous Pennsylvania. Revenue was also boosted by new dispensary openings in states such as Massachusetts and Arizona.

Separately, the company announced yet another asset buy. It has signed a definitive agreement to purchase London-based EMMAC Life Sciences, which it describes as "the largest vertically integrated independent cannabis company in Europe." The base price is $286 million, 85% of which will be paid in subordinate Curaleaf voting shares and the remainder in cash. EMMAC can earn up to an additional $57 million more in a similar cash/stock mix if it hits certain performance milestones.

Prior to the results announcement, Curaleaf stock closed nearly 16% higher Tuesday, eclipsing the 1.4% gain of the S&P 500 index.


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Curaleaf Holdings, Inc. Stock Quote
Curaleaf Holdings, Inc.
$6.12 (0.74%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.